RBC Capital analyst Gregory Renza downgraded Alpine Immune Sciences to Sector Perform from Outperform with a price target of $65, up from $41, after the company entered a definitive agreement to be acquired by Vertex Pharmaceuticals (VRTX) for $4.9B or $65 per share. With no pipeline overlapping, RBC sees a high likelihood of the deal closing.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALPN: